The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review

K. L. Wycislo, T. M. Fan

Research output: Contribution to journalArticle

Abstract

Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.

Original languageEnglish (US)
Pages (from-to)759-769
Number of pages11
JournalJournal of veterinary internal medicine
Volume29
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

osteosarcoma
immunotherapy
systematic review
Osteosarcoma
Immunotherapy
Canidae
dogs
metastasis
therapeutics
Dogs
Neoplasm Metastasis
neoplasms
Therapeutics
lungs
Neoplasms
Lung
Neoplasm Micrometastasis
Cytotoxins
Disease Management
adjuvants

Keywords

  • Bone sarcoma
  • Cellular immunity
  • Immunotherapeutics
  • Metastases

ASJC Scopus subject areas

  • veterinary(all)

Cite this

The Immunotherapy of Canine Osteosarcoma : A Historical and Systematic Review. / Wycislo, K. L.; Fan, T. M.

In: Journal of veterinary internal medicine, Vol. 29, No. 3, 01.05.2015, p. 759-769.

Research output: Contribution to journalArticle

@article{00a5cc1f53b94057a2218d7a6072de86,
title = "The Immunotherapy of Canine Osteosarcoma: A Historical and Systematic Review",
abstract = "Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.",
keywords = "Bone sarcoma, Cellular immunity, Immunotherapeutics, Metastases",
author = "Wycislo, {K. L.} and Fan, {T. M.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/jvim.12603",
language = "English (US)",
volume = "29",
pages = "759--769",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The Immunotherapy of Canine Osteosarcoma

T2 - A Historical and Systematic Review

AU - Wycislo, K. L.

AU - Fan, T. M.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.

AB - Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in humans. Despite dose intensification with conventional cytotoxic therapies, survival times for dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, with the principal cause of mortality being the development of pulmonary metastases. Given the therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is clinically justified. Evidence suggests that osteosarcoma is an immunogenic tumor, and development of immunotherapies for the treatment of microscopic lung metastases might improve long-term outcomes. In this review, the history and foundational knowledge of immune interactions to canine osteosarcoma are highlighted. In parallel, immunotherapeutic strategies that have been explored for the treatment of canine osteosarcoma are summarized. With a greater understanding and awareness for how the immune system might be redirected toward combating osteosarcoma metastases, the rational development of diverse immune strategies for managing osteosarcoma holds substantial promise for transforming the therapeutic landscape and improving disease management in both dogs and human beings.

KW - Bone sarcoma

KW - Cellular immunity

KW - Immunotherapeutics

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=84929840497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929840497&partnerID=8YFLogxK

U2 - 10.1111/jvim.12603

DO - 10.1111/jvim.12603

M3 - Article

C2 - 25929293

AN - SCOPUS:84929840497

VL - 29

SP - 759

EP - 769

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 3

ER -